Tag: Cancer: Cervical
Poor Sensitivity for HPV 16/18 in Minor Abnormal Cytology
Review: pooled sensitivity of HPV 16/18 genotyping for CIN3+ about 70 percent for ASC-US or LSIL
Standard of Care Underused for Locally Advanced Cervical Cancer
Despite improved overall survival with standard of care, less than half of patients receive SOC treatment
Recommendations for Secondary Prevention of Cervical Cancer
HPV DNA testing recommended in all resource settings; HIV+ should undergo screening more often
Less Frequent Cervical CA Screens May Be OK After HPV Vaccine
Less testing could reduce risk of false-positives and save money, researchers say
Ovarian Preservation Doesn’t Impact Prognosis in Cervical CA
Risk factors for metastases include stage IIB, cervical stromal invasion, lymph node metastasis
Low Incidence of Cervical Cancer, CIN3+ for HPV-Negative Women
Low incidence may support extension of cervical screening interval beyond five years
More Evidence HPV Vaccine Protects Against Cervical Cancer
Protection appears to occur even when only one or two of the recommended doses are given
ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA
Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm
Approval of First HPV Test for Use With SurePath Preservative Fluid
For cervical cells obtained for Pap test, collected in SurePath Preservative Fluid
CDC: Majority of HPV-Linked Cancers Are Preventable
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers
